Medtronic Receives FDA Approval for "Breakthrough" Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease

Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for its Harmony ™ Transcatheter Pulmonary Valve (TPV), the 1st minimally invasive therapy created to treat patients with a specific type of congenital heart defect of the right ventricle, one of the four chambers of the heart, which makes it difficult for blood to travel from the heart to the lungs.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news